Welcome to our dedicated page for Becton Dickinson & Co news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & Co stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology company whose news flow reflects activity across medical discovery, diagnostics, drug delivery and interventional care. On this page, readers can follow company-issued updates and third-party coverage related to BD’s operations, product clearances, collaborations and corporate developments.
Recent BD news highlights regulatory milestones, such as U.S. FDA 510(k) clearance for the EnCor EnCompass™ Breast Biopsy and Tissue Removal System, a multi-modality breast biopsy platform designed to support early detection and diagnosis of breast disease. Other announcements showcase BD’s role in supporting the pharmaceutical supply chain, including investments to expand production of BD Neopak™ Glass Prefillable Syringes in the United States to help meet growing demand for biologic and GLP-1 drug delivery.
Investors and observers can also track BD’s clinical and surgical innovations, including milestones with Phasix™ Mesh for hernia prevention in Europe and progress in the PREVENT trial, as well as the European launch of the BD Surgiphor™ Surgical Wound Irrigation System. In diagnostics and research, BD reports collaborations with institutions such as the University of Pennsylvania’s Institute for Immunology and Immune Health, and product updates like new IVDR-certified VIASURE assays for the BD MAX™ System and expanded configurations of BD FACSDiscover™ A8 Cell Analyzers.
Corporate governance and financial communications feature in BD’s news as well, with items such as leadership appointments in investor relations and notices regarding annual shareholder meetings. This news feed offers a centralized view of BD’s product pipeline, strategic investments, partnerships and regulatory events, providing context for how the company positions itself within the medical technology landscape.
BD (Becton, Dickinson and Company) (NYSE: BDX), a prominent medical technology leader, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 2:15 p.m. Eastern Time. The presentation will be accessible via live webcast on BD's investor relations website, with a replay available afterward. BD focuses on advancing health through technology, diagnostics, and care delivery, supporting healthcare providers and enhancing patient outcomes globally.
BD (Becton, Dickinson and Company) has launched the BD Veritor™ At-Home COVID-19 Test, now available through Everly Health and Southeastern Grocers, including Fresco y Más, Harveys Supermarket, and Winn-Dixie. The test is unique as it utilizes a smartphone app to interpret results, ensuring accuracy without human error. BD emphasizes the test's importance for community safety amidst rising COVID-19 cases, especially during the holiday season. The test is available online and in-store, enabling broad access for consumers.
BD (Becton, Dickinson and Company) announced the formation of a nine-person board of directors for Embecta Corp., which will hold BD's Diabetes Care business after the planned spinoff. The board will be led by David F. Melcher and include notable members such as Claire Pomeroy and Christopher R. Reidy. Devdatt Kurdikar will serve as CEO of Embecta. The spinoff is expected to be completed in Q2 2022, pending regulatory approvals. The governance structure includes various committees, and directors will serve staggered terms.
BD (Becton, Dickinson and Company) has successfully acquired Scanwell Health Inc., a pioneer in smartphone-enabled at-home medical testing. The acquisition aims to enhance BD's digital capabilities for at-home diagnostics, including COVID-19 and other infectious diseases. The BD Veritor™ At-Home COVID-19 Test leverages smartphone technology for accurate result interpretation. Although transaction details were not disclosed, it is anticipated to have an immaterial impact on BD's fiscal 2022 financials. This move underscores BD's commitment to innovative health solutions.
BD (Becton, Dickinson and Company) (NYSE: BDX) has expanded its BD COR™ System with the introduction of the MX instrument, designed for high-throughput molecular testing for infectious diseases, including a new CE-marked assay for sexually transmitted infections. The MX instrument, part of a modular system alongside the PX and GX instruments, can process 1,700 specimens and deliver up to 1,000 results in 24 hours, enhancing laboratory efficiency. The platform automates testing workflows, improving diagnostics for women's health and STIs.
Summary not available.
BioGX announced that its SARS-CoV-2 diagnostic portfolio can detect the Omicron variant (B.1.1.529). The surveillance program includes in-silico analyses confirming detection across all variants of interest. BioGX's COVID-19 RT-PCR tests are compatible with several real-time PCR platforms, notably the Xfree COVID-19 Direct RT-PCR, which is FDA authorized for multiple specimen types. This test offers extraction-free options, enhancing workflow efficiency. BioGX operates under ISO 13485 standards, providing over 60 multiplex real-time PCR products worldwide.
BD (Becton, Dickinson and Company) announced that the new name for its upcoming spinoff of the Diabetes Care business will be embecta. This independent, publicly-traded company aims to empower those living with diabetes while maintaining a connection to BD's legacy. The spinoff is expected to finalize in the second quarter of 2022. Devdatt Kurdikar will serve as CEO, leading a diverse team focused on innovation and improvement in diabetes care products. The name reflects the company's commitment and heritage, aiming to enhance the quality of life for diabetes patients globally.
BD (Becton, Dickinson and Company) has acquired Venclose, Inc., a leader in treatments for chronic venous insufficiency (CVI). This acquisition enhances BD's portfolio of venous disease technologies, leveraging Venclose's innovative Radio Frequency (RF) ablation system that is designed for efficiency and versatility. CVI affects up to 40% of women and 17% of men in the U.S. The dual heating length of the Venclose System allows multiple vein segments to be ablated with one catheter, potentially reducing post-operative pain for patients. The financial impact of the deal is expected to be immaterial for BD's fiscal 2022.
BD (Becton, Dickinson and Company) (NYSE: BDX) issued a statement confirming the effectiveness of its rapid antigen and PCR tests for detecting the COVID-19 Omicron variant. Conducting an analysis based on genome sequences up to Nov. 29, 2021, BD remains confident that its testing methods will identify this new variant. To date, the company has evaluated over 3.5 million SARS-CoV-2 genomes and reported no undetectable variants. BD emphasizes the importance of reliable testing in combating COVID-19's spread and will continue rigorous performance monitoring.